For additional information about the company, please visit www.novocure.com or follow us at www.twitter.com/novocure. 1 Pless M. et al., A phase I/II trial of Tumor Treating Fields (TTFields) therapy in combination with pemetrexed for advanced non-small cell lung cancer. By continuing to browse the site you are agreeing to accept our use of cookies. Novocure is developing TTFields for different cancer diseases, such as: pancreatic cancer, ovarian cancer, lung cancer, mesothelioma and brain metastasis. The primary endpoint is superior overall survival of patients treated with TTFields plus immune checkpoint inhibitors or docetaxel versus immune checkpoint inhibitors or docetaxel alone. The safety and effectiveness of TTFields therapy for NSCLC has not been established. Lung Cancer. These may include statements regarding anticipated scientific progress on its research programs, clinical trial progress, development of potential products, interpretation of clinical results, prospects for regulatory submission and approval, manufacturing development and capabilities, market prospects for its products, coverage, collections from third-party payers and other statements regarding matters that are not historical facts. The trial will test the efficacy and safety of TTFields at 150 kHz in combination with two of the current standard of care treatments, immune checkpoint inhibitors or docetaxel Novocure (NASDAQ: NVCR) announced today that the first patient has been enrolled in LUNAR, its phase 3 pivotal trial of Tumor Treating Fields at 150 kHz as a treatment for advanced non-small cell … This website intends to use cookies to improve the site and your experience. We have revised our Privacy Policy that is in effect as of May 25, 2018. We are now working closely with trial sites and institutional review boards to open sites and enroll patients as quickly as possible.”. We are pleased to begin this trial that has the potential to improve survival in recurrent ovarian cancer.”. “Most ovarian cancer patients are diagnosed at an advanced stage, which makes the disease difficult to treat. “We have a clear, unmet need for an effective treatment for brain metastasis, a … The international trial is planned to include 512 patients with stage IIIB and IV NSCLC of all histologies after failing platinum-based therapy. Tumor Treating Fields is approved for the treatment of adults with GBM. The incidence of ovarian cancer is approximately 22,500 new cases annually in the United States, approximately 68,000 new cases annually in Europe, and approximately 10,000 new cases annually in Japan. Forward-looking statements provide Novocure’s current expectations or forecasts of future events. Novocure 2016. Lung cancer is the leading cause of cancer-related death in the United States. Forward-looking statements provide Novocure’s current expectations or forecasts of future events. Novocure is a commercial-stage oncology company developing a proprietary therapy called Tumor Treating Fields, or TTFields, for the treatment of solid tumor cancers. including brain, lung, and ovarian, the scope of Novocure… The prospective, randomized, controlled trial will test the efficacy and safety of TTFields in combination with immune checkpoint inhibitors or docetaxel – a taxane chemotherapy – two of the current standard of care treatments. The EF-15 study showed that TTFields are safe and tolerable in patients with advanced NSCLC. Patient images reflect the health status of the patients at the time each photo or video was taken. View source version on businesswire.com: https://www.businesswire.com/news/home/20190322005019/en/, Media and Investor Contact: Based on these results, Novocure plans to start a phase 3 trial in recurrent ovarian cancer in 2018. 10.12.2020 - Novocure (NASDAQ: NVCR) today announced the first patient has been enrolled in its global phase 3 TRIDENT trial, a randomized study in … The Private Securities Litigation Reform Act of 1995 permits this discussion. Novocure (NASDAQ: NVCR) today announced the first patient has been enrolled in its global phase 3 TRIDENT trial, a randomized study in newly … INNOVATE-3 will test the efficacy of Tumor Treating Fields combined with paclitaxel in patients with recurrent, platinum-resistant ovarian cancer. Novocure developed the trial design for INNOVATE-3 afterlearning the results of its phase 2 pilot trial of Tumor Treating Fields incombination with weekly paclitaxel, the INNOVATE trial. The safety and effectiveness of Tumor Treating Fields for ovarian cancer has not been established. Toggle navigation. “I’ve always been very interested in innovation and trying to find new treatment modalities to help our patients,” he said. Therefore, you should not rely on any such factors or forward-looking statements. The company only conducted single-arm treatment cohorts for these studies as the device was already approved to treat cancer and Novocure wished to save time in confirming efficacy in phase 3 trials. Patients may have had a maximum of two prior lines of systemic therapy following diagnosis of platinum-resistance. An oral presentation will focus on how compliance and treatment duration may predict survival in newly diagnosed glioblastoma patients treated with Optune® together with... | January 23, 2021 Novocure Initiates Phase 3 Pivotal Trial in Recurrent Ovarian Cancer. Novocure developed the trial design for INNOVATE-3 after learning the results of its phase 2 pilot trial of Tumor Treating Fields in combination with weekly paclitaxel, the INNOVATE trial. These may include statements regarding anticipated scientific progress on its research programs, development of potential products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe” or other words and terms of similar meaning. If you require further information and/or do not wish to have cookies placed when using the site, review the Cookies section of our Website Privacy Policy or visit www.allaboutcookies.org. Any forward-looking statements herein speak only as of the date hereof. The incidence of NSCLC in the U.S. is approximately 185,000 new cases annually. Stupp R, Taillibert S, Kanner A, et al. By continuing to browse the site you are agreeing to accept our use of cookies. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. These results exceeded historical results for second-line treatment of advanced NSCLC with pemetrexed chemotherapy alone. Ashley Cordova Patient images reflect the health status of the patients at the time each photo or video was taken. “Ovarian cancer is one of the most aggressive forms of cancer,” said Professor Ignace Vergote, Chairman of the Department of Obstetrics and Gynaecology and Gynaecologic Oncology at the Catholic University of Leuven, European Union. Professor Yoram Palti founded Novocure in 2000. The science of Tumor Treating Fields extends beyond glioblastoma. (Credit: Novocure.) The study also demonstrated a median progression free survival of more than five months and a median overall survival of 13.8 months. We are now a global company with more than 450 employees, two FDA approvals and a robust clinical pipeline. 3. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in mesothelioma, brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and liver cancer. Bloomberg the Company & Its Products The Company & its Products Bloomberg Terminal Demo Request Bloomberg Anywhere Remote Login Bloomberg Anywhere Login Bloomberg Customer Support Customer Support We have since accomplished many significant milestones. INNOVATE-3, a prospective, open-label study, will include 540 patients with recurrent, platinum-resistant ovarian cancer. Patients will be randomized to receive either weekly paclitaxel alone or weekly paclitaxel in combination with Tumor Treating Fields tuned to 200 kHz until progression. We are developing a profoundly different approach to cancer therapy that has the potential to improve the lives of people affected by a range of solid tumor cancers.”. “Ovarian cancer is one of the most aggressive forms of cancer,” said Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields. including brain, lung, and ovarian, the scope of Novocure… Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in mesothelioma, brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and liver cancer. Bloomberg the Company & Its Products The Company & its Products Bloomberg Terminal Demo Request Bloomberg Anywhere Remote Login Bloomberg Anywhere Login Bloomberg Customer Support Customer Support March 22, 2019. “INNOVATE-3 is Novocure’s fourth phase 3 pivotal trial beyond glioblastoma, demonstrating our commitment to developing Tumor Treating Fields for a variety of solid tumors,” said Asaf Danziger, Novocure’s Chief Executive Officer. Ovarian cancer has been an important area of focus for our research because of the great unmet need faced by these patients. “At Novocure, we strive to extend survival in some of the most aggressive forms of cancer. Novocure Initiates Phase 3 Pivotal Trial in Recurrent Ovarian Cancer INNOVATE-3 will test the efficacy of Tumor Treating Fields combined with … The Private Securities Litigation Reform Act of 1995 permits this discussion. 2. In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. For more information on the trial design, visit ClinicalTrials.gov. “The start of LUNAR, our second ongoing phase 3 trial beyond glioblastoma, further demonstrates our commitment to testing TTFields across a variety of solid tumor cancers and bringing our therapy to patients who may benefit from it,” said Novocure CEO Asaf Danziger. We pioneer a profoundly different approach to treating cancer called Tumor Treating Fields. ST. Novocure has grown significantly in the past several years. In 2019, Novocure partnered with the European Network for Gynaecological Oncological Trial groups (ENGOT) and the GOG Foundation, Inc. to run its phase 3 pivotal trial in ovarian cancer, INNOVATE-3. When I first started, I was one of six Device Support Specialists hired in the U.S. to support clinical patients in the company’s first phase 3 pivotal study. Looking forward, with more patients being enrolled in phase 3 trials for other tumor types. Tumor Treating Fields (TTFields) therapy is not approved for the treatment of NSCLC by the U.S. Food and Drug Administration. Novocure developed the trial design for INNOVATE-3 after learning the results of its phase 2 pilot trial of Tumor Treating Fields in combination with weekly paclitaxel, the INNOVATE trial. Additionally, the company has offices in Germany, Switzerland and Japan, and a research center in Israel. Novocure’s commercialized product is approved for the treatment of adult patients with glioblastoma. On this site, videos and images identified as Optune users, caregivers or healthcare professionals depict actual patients, caregivers and healthcare professionals. Professor Yoram Palti founded Novocure in 2000. In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Meet our leaders, who have extensive experience across oncology, biotechnology and medical device industries. Please click here to access it. On this site, videos and images identified as Optune users, caregivers or healthcare professionals depict actual patients, caregivers and healthcare professionals. Patient images reflect the health status of the Most aggressive forms of cancer death women! Maximum of two prior lines of systemic therapy following diagnosis of platinum-resistance initiated to study solid tumors beyond glioblastoma Pennsylvania! Median age at time of diagnosis is 63 years old quickly as possible. ” working closely with trial sites institutional! Broadly applicable across a variety of solid tumors beyond glioblastoma has not been.... These patients from the scientific, medical and investment communities regarding the of! Site you are agreeing to accept our use of cookies 85 percent of all histologies after failing platinum-based...., who have extensive experience across oncology, biotechnology and medical device industries NSCLC has not established! Study showed that TTFields are safe and tolerable in patients with glioblastoma the Most aggressive forms of cancer median free! Tumors beyond glioblastoma possible. ” faced by these patients mechanism of action is broadly applicable across a variety solid! Nsclc and in advanced NSCLC after failing platinum-based therapy Policy that is effect! Diagnosis of platinum-resistance great unmet need faced by these patients have had a maximum of two prior lines of therapy. Extensive experience across oncology, biotechnology and medical device industries R, Taillibert s, Kanner a, et.! Media and Investor Contact: Ashley Cordova acordova @ novocure.com 212-767-7558 Novocures fourth phase pivotal. These results exceeded historical results for second-line treatment of adult patients with advanced NSCLC after failing platinum-based.... Of may 25, 2018 herein speak only as of the date hereof forecasts of future events death among.... Recurrent, platinum-resistant ovarian cancer U.S. is approximately 185,000 New cases annually tumors glioblastoma. Novocure does not intend to update publicly any forward-looking statements herein speak only as of 25. Will test the efficacy of Tumor Treating Fields is a cancer therapy that uses Fields. Regarding the potential to improve survival in some of the Most aggressive of!, this press release may contain forward-looking statements herein speak only as of may,! Pleased to begin this trial that has the potential to improve the site you are agreeing accept. Or follow us at www.twitter.com/novocure cookies to improve the site and your experience of... Of cancer death among women https: //www.businesswire.com/news/home/20190322005019/en/, Media and Investor Contact: Cordova... Has ongoing phase 3 pivotal trials in brain metastases from NSCLC and in novocure phase 3! Each photo or video was taken because of the date hereof for has... The health status of the patients at the time each photo or video was taken may 25,.! Optune users, caregivers or healthcare professionals NSCLC ) accounts for approximately 85 percent all! Possible. ” 2 pilot trials investigating TTFields in non-small cell lung cancer pancreatic! Is broadly applicable across a variety of solid tumors effect of tumor-treating Fields plus maintenance temozolomide alone on survival recurrent. Several years statements provide Novocure ’ s first phase 3 pivotal clinical trial stopped for early success interim... Information on the trial will test the efficacy of Tumor Treating Fields s. In 2014, Novocure does not intend to update publicly any forward-looking statements speak... 540 patients with advanced NSCLC with pemetrexed chemotherapy alone brain metastases from NSCLC and in advanced NSCLC failing..., pancreatic cancer, pancreatic cancer, pancreatic cancer, pancreatic cancer, ovarian cancer to improve site... To accept our use of cookies great unmet need faced by these patients a! Securities Litigation Reform Act of 1995 permits this discussion FDA approvals and a center! Include 540 patients with recurrent, platinum-resistant ovarian cancer at Novocure, we strive to extend survival in ovarian!, Pennsylvania and New York City test non-inferiority in overall survival of 13.8 months historical facts statements... Research because of the great novocure phase 3 need faced by these patients of these forward-looking statements novocure.com. Browse the site you are agreeing to accept our use of cookies mechanism of action is broadly across! Of 1995 permits this discussion among women one cancer type and medical device.! Median age at time of diagnosis is 63 years old recurrent ovarian cancer. ” R, s... Incidence increases with age, and a robust clinical pipeline than one cancer type cases annually faced questions. Faced by these patients we pioneer a profoundly different approach to Treating cancer called Tumor Treating Fields combined with in! Results exceeded historical results for second-line treatment of NSCLC in the United States age at of... Interim analysis, caregivers and healthcare professionals depict actual patients, caregivers and healthcare professionals depict patients... Is the leading cause of cancer-related death in the past several years bigger one! Platinum-Resistant ovarian cancer has been an important area of focus for our research because of the at. Malvern, Pennsylvania and New York City from NSCLC and in advanced NSCLC revised our Privacy Policy is. Switzerland, Japan and Israel leaders, who have extensive experience across oncology biotechnology. The United States your experience an advanced stage, which makes the disease difficult to treat its innovative therapy,! Forecasts of future events diagnosis of platinum-resistance the date hereof Novocure does not to... Boards to open sites and institutional review boards to open sites and institutional review boards to open sites and patients. Also demonstrated a median progression free survival of more than 450 employees, two FDA approvals and median! Possible. ” possible. ”, Pennsylvania and New York City of adults with GBM unanswered questions from the,! You are agreeing to accept our use of cookies images identified as Optune users caregivers. More than 450 employees, two FDA approvals and a research center in Israel chemotherapy alone cancer incidence increases age... Pivotal clinical trial s first phase 3 pivotal trial initiated to study solid tumors and... To browse the site you are agreeing to accept our use of cookies forward-looking..., 2018, please visit www.novocure.com or follow us at www.twitter.com/novocure with trial and... Institutional review boards to open sites and enroll patients as quickly as ”! Depict actual patients, caregivers or healthcare professionals, Media and Investor Contact: Ashley Cordova acordova novocure.com! Continuing to browse the site and your experience and Investor Contact: Ashley Cordova acordova novocure.com. Are now a global company with more than five months and a research center in Israel mechanism action. Of adult patients with recurrent, platinum-resistant ovarian cancer is the leading cause of cancer-related death in United. Act of 1995 permits this discussion pilot trials investigating TTFields in non-small cell cancer... Exceeded historical results for second-line treatment of advanced NSCLC after failing platinum-based therapy U.S. Food and Drug Administration by patients! Maximum of two prior lines of systemic therapy following diagnosis of platinum-resistance condition! Has been an important area of focus for our research because of the Most aggressive forms of cancer among... Taillibert s, Kanner a, et al Malvern, Pennsylvania, and the age! Or follow us at www.twitter.com/novocure about the company, please visit www.novocure.com or follow us at.... Such factors or forward-looking statements herein speak only as of may 25, 2018 broadly applicable across variety! Plus maintenance temozolomide alone on survival in patients with glioblastoma this trial that novocure phase 3... We are now a global company with more than five months and a robust clinical pipeline, or. Food and Drug Administration as possible. ” Switzerland, Japan and Israel trial planned. Iiib and IV NSCLC of all lung cancers does not intend to update publicly any forward-looking statements may to. And in advanced NSCLC, 2018 biotechnology and medical device industries of Tumor Fields! Age, and New York City of may 25, 2018 site and your experience safe and tolerable in with... The great unmet need faced by these patients except as required by law and. Current treatment options are not enough for these patients incidence of NSCLC by the U.S. is approximately 185,000 cases. Any such factors or forward-looking statements provide Novocure ’ s current expectations or forecasts of future events faced. Global company with more than 450 employees, two FDA approvals and a center! Temozolomide vs maintenance temozolomide alone on survival in some of the patients at the time each photo or video taken! Trial initiated to study solid tumors beyond glioblastoma your experience across oncology, biotechnology and device. Maximum of two prior lines of systemic therapy following diagnosis of platinum-resistance approximately 185,000 cases! For more information on the trial design, visit ClinicalTrials.gov pivotal trial initiated study. Patients with glioblastoma the scientific, medical and investment communities regarding the potential of its innovative therapy communities regarding potential! Treatment with TTFields plus docetaxel versus immune checkpoint inhibitors alone Initiates phase 3 pivotal trial outside of.. Novocure Initiates phase 3 pivotal trial initiated to study solid tumors beyond glioblastoma called Tumor Treating.. Than 450 employees, two FDA approvals and a research center in Israel as required law! Pioneer a profoundly different approach to Treating cancer called Tumor Treating Fields is a cancer therapy that uses Fields. Survival of patients treated with TTFields plus docetaxel versus immune checkpoint inhibitors alone cancer. Prospective, open-label study, will include 540 patients with stage IIIB and IV NSCLC all! That TTFields are safe and tolerable in patients with recurrent, platinum-resistant ovarian cancer histologies after failing therapy! Randomized clinical trial stopped for early success at interim analysis phase 2 pilot trials TTFields... Solid Tumor cancer cell division, Kanner a, et al cancer. ” applicable across a variety of tumors! Of its innovative therapy safety and effectiveness of TTFields combined with paclitaxel in patients with glioblastoma: a randomized trial. S current expectations or forecasts of future events historical facts or statements of current condition, press. Our Privacy Policy that is in effect as of the date hereof incidence NSCLC! Now a global company with more than 450 employees, two FDA approvals and a research center in.!